The status of gene therapy for brain tumors

Expert Opinion on Biological Therapy

Volumn 7, Issue 2, 2007, Pages 197-208

  Fulci, Giulia ^a,b   Chiocca, E Antonio ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Brain tumors; Clinical trials; Gene therapy; Preclinical research

Indexed keywords

1716; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BETA GALACTOSIDASE; CYCLOPHOSPHAMIDE; G 207; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LENTIVIRUS VECTOR; LIPOSOME; MONOCLONAL ANTIBODY; NAKED DNA; NANOPARTICLE; NEWCASTLE DISEASE VIRUS VECTOR; NUCLEOSIDE ANALOG; ONCOLYTIC HERPES VIRUS; ONCOLYTIC PARAMYXOVIRUS; ONCOLYTIC VIRUS; ONYX 015; PARVOVIRUS VECTOR; PROTEIN P53; RETROVIRUS VECTOR; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; TEMOZOLOMIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

BRAIN TUMOR; CANCER GENE THERAPY; CELL HETEROGENEITY; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EDEMA; GENE DELIVERY SYSTEM; GENETIC ENGINEERING; GLIOBLASTOMA; GLIOMA; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; MESENCHYME CELL; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ANIMALS; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE THERAPY; HUMANS;

EID: 33846674557     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.2.197     Document Type: Review

References (118)

1. LOUIS DN, POMEROY SL, CAIRNCROSS JG: Focus on central nervous system neoplasia. Cancer Cell (2002) 1(2):125-128. • Comprehensive review on brain tumors that includes all their histological features relevant to design treatments.
2. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996. •• First clinical trial showing significant improvement in the treatment of malignant gliomas.
3. KLEIHUES P, CAVENEE WK: Pathology and Genetics of Tumors of the Nervous System. Kleihues P, Cavenee WK (Eds), International Agency for Research on Cancer, Lyon, France (1997).
4. KIRSCH M, SCHACKERT G, BLACK PM: Anti-angiogenic treatment strategies for malignant brain tumors. J. Neurooncol. (2000) 50(1-2):149-163.
5. JENDROSSEK V, BELKA C, BAMBERG M: Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Investig. Drugs (2003) 12(12):1899-1924.
6. EHTESHAM M, BLACK KL, YU JS: Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control (2004) 11(3):192-207.
7. GUERIN C, OLIVI A, WEINGART JD, LAWSON HC, BREM H: Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs (2004) 22(1):27-37.
8. LAM PY, BREAKEFIELD XO: Potential of gene therapy for brain tumors. Hum. Mol. Genet. (2001) 10(7):777-787.
9. CHIOCCA EA, AGHI M, FULCI G: Viral therapy for glioblastoma. Cancer J. (2003) 9(3):167-179.
10. AGHI M, RABKIN S: Viral vectors as therapeutic agents for glioblastoma. Curr. Opin. Mol. Ther. (2005) 7(5):419-430.
11. ICHIMURA K, BOLIN MB, GOIKE HM, SCHMIDT EE, MOSHREF A, COLLINS VP: Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities. Cancer Res. (2000) 60(2):417-424.
12. FULCI G, LABUHN M, MAIER D et al.: p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene (2000) 19(33):3816-3822.
13. YAZAWA K, FUJIMORI M, AMANO J et al.: Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. (2000) 7(2):269-274.
14. AGRAWAL N, BETTEGOWDA C, CHEONG I et al.: Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc. Natl. Acad. Sci. USA (2004) 101(42):15172-15177.
15. VASSAUX G, NITCHEU J, JEZZARD S, LEMOINE NR: Bacterial gene therapy strategies. J. Pathol. (2006) 208(2):290-298.
16. ABOODY KS, BROWN A, RAINOV NG et al.: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. USA (2000) 97(23):12846-12851.
17. GLASS R, SYNOWITZ M, KRONENBERG G et al.: Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J. Neurosci. (2005) 25(10):2637-2646.
18. BENEDETTI S, PIROLA B, POLLO B et al.: Gene therapy of experimental brain tumors using neural progenitor cells. Nat. Med. (2000) 6(4):447-450.
19. YOSHIDA J, MIZUNO M: Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J. Neurooncol. (2003) 65(3):261-267.
20. VOGES J, RESZKA R, GOSSMANN A et al.: Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. (2003) 54(4):479-487. • First clinical trial using a non-viral gene therapy vector in combination with novel imaging and delivery techniques; this trial provides important information about existing gene therapy limits.
21. MIZUNO M, YOSHIDA J: [Gene therapy for malignant glioma]. Nippon Rinsho (2005) 63(3):469-475.
22. RAINOV NG, REN H: Clinical trials with retrovirus mediated gene therapy-what have we learned? J. Neurooncol. (2003) 65(3):227-236.
23. VECIL GG, LANG FF: Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. (2003) 65(3):237-246.
24. INOUE R, MOGHADDAM KA, RANASINGHE M, SAEKI Y, CHIOCCA EA, WADE-MARTINS R: Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene Ther. (2004) 11(15):1195-1204.
25. REINBLATT M, PIN RH, BOWERS WJ, FEDEROFF HJ, FONG Y: Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. Ann. Surg. Oncol. (2005) 12(12):1025-1036.
26. SAYDAM O, GLAUSER DL, HEID I et al.: Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol. Ther. (2005) 12(5):803-812.
27. LI C, BOWLES DE, VAN DYKE T, SAMULSKI RJ: Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. (2005) 12(12):913-925.
28. LINK N, AUBEL C, KELM JM et al.: Therapeutic protein transduction of mammalian cells and mice by nucleic acid-free lentiviral nanoparticles. Nucleic Acids Res. (2006) 34(2):e16.
29. KIRN D, MARTUZA RL, ZWIEBEL J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. (2001) 7(7):781-787.
30. FULCI G, CHIOCCA EA: Oncolytic viruses for the therapy of brain tumors and other solid malignancies: a review. Front. Biosci. (2003) 8:e346-e360.
31. AGHI M, MARTUZA RL: Oncolytic viral therapies - the clinical experience. Oncogene (2005) 24(52):7802-7816.
32. COLE C, QIAO J, KOTTKE T et al.: Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med. (2005) 11(10):1073-1081.
33. KOMAROVA S, KAWAKAMI Y, STOFF-KHALILI MA, CURIEL DT, PEREBOEVA L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. (2006) 5(3):755-766.
34. THORNE SH, NEGRIN RS, CONTAG CH: Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 311(5768):1780-1784.
35. POST DE, FULCI G, CHIOCCA EA, VAN MEIR EG: Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. (2004) 4(1):41-51.
36. DONG JY, WORARATANADHARM J: Gene therapy vector design strategies for the treatment of cancer. Future Oncol. (2005) 1(3):361-373.
37. LAGE H: Potential applications of RNA interference technology in the treatment of cancer. Future Oncol. (2005) 1(1):103-113.
38. IZQUIERDO M, MARTIN V, DE FELIPE P et al.: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. (1996) 3(6):491-495.
39. RAM Z, CULVER KW, OSHIRO EM et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. (1997) 3(12):1354-1361.
40. KLATZMANN D, VALERY CA, BENSIMON G et al.: A Phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum. Gene Ther. (1998) 9(17):2595-2604.
41. SHAND N, WEBER F, MARIANI L et al.: A Phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. (1999) 10(14):2325-2335.
42. ADACHI N, KONU DL, FREI K, YONEKAWA Y: [The HSV-TK/GCV gene therapy in five cases of recurrent glioblastoma multiforme]. No Shinkei Geka (2000) 28(10):865-871.
43. HARSH GR, DEISBOECK TS, LOUIS DN et al.: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J. Neurosurg. (2000) 92(5):804-811.
44. PACKER RJ, RAFFEL C, VILLABLANCA JG et al.: Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. (2000) 92(2):249-254.
45. RAINOV NG: A Phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. (2000) 11(17):2389-2401. •• Clinical trial that demonstrated the lack of improvement in brain tumor therapy when using retrovirus gene therapy systems; this study has pushed clinicians and researchers to study new vector systems for gene therapy.
46. PALU G, CAVAGGIONI A, CALVI P et al.: Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Ther. (1999) 6(3):330-337.
47. COLOMBO F, BARZON L, FRANCHIN E et al.: Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther. (2005) 12(10):835-848.
48. SANDMAIR AM, LOIMAS S, PURANEN P et al.: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. (2000) 11(16):2197-2205.
49. TRASK TW, TRASK RP, AGUILAR-CORDOVA E et al.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. (2000) 1(2):195-203.
50. GERMANO IM, FABLE J, GULTEKIN SH, SILVERS A: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. (2003) 65(3):279-289.
51. LANG FF, BRUNER JM, FULLER GN et al.: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. (2003) 21(13):2508-2518.
52. IMMONEN A, VAPALAHTI M, TYYNELA K et al.: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. (2004) 10(5):967-972.
53. MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. (2000) 7(10):867-874.
54. RAMPLING R, CRUICKSHANK G, PAPANASTASSIOU V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. (2000) 7(10):859-866.
55. CHIOCCA EA, ABBED KM, TATTER S et al.: A Phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. (2004) 10(5):958-966.
56. FREEMAN AI, ZAKAY-RONES Z, GOMORI JM et al.: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. (2006) 13(1):221-228.
57. PUUMALAINEN AM, VAPALAHTI M, AGRAWAL RS et al.: Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. (1998) 9(12):1769-1774.
58. NESTLER U, WAKIMOTO H, SILLER-LOPEZ F et al.: The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J. Neurooncol. (2004) 67(1-2):177-188.
59. JIANG C, WECHUCK JB, GOINS WF et al.: Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification. J. Virol. (2004) 78(17):8994-9006.
60. KASAI K, SAEKI Y: DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr. Gene Ther. (2006) 6(3):303-314.
61. CHEN MY, HOFFER A, MORRISON PF et al.: Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J. Neurosurg. (2005) 103(2):311- 319.
62. SAITO R, KRAUZE MT, NOBLE CO et al.: Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J. Neurosci. Methods (2006) 154(1-2):225-232.
63. SAITO R, KRAUZE MT, BRINGAS JR et al.: Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. (2005) 196(2):381-389.
64. OSHIRO EM, VIOLA JJ, OLDFIELD EH et al.: Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells. Cancer Gene Ther. (1995) 2(2):87-95.
65. DRIESSE MJ, ESANDI MC, KROS JM et al.: Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther. (2000) 7(16):1401-1409.
66. CHIRMULE N, PROPERT K, MAGOSIN S, QIAN Y, QIAN R, WILSON J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. (1999) 6(9):1574-1583.
67. WAKIMOTO H, JOHNSON PR, KNIPE DM, CHIOCCA EA: Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther. (2003) 10(11):983-990.
68. NILAVER G, MULDOON LL, KROLL RA et al.: Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA (1995) 92(21):9829-9833.
69. BARNETT FH, RAINOV NG, IKEDA K et al.: Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7. Cancer Gene Ther. (1999) 6(1):14-20.
70. SCHELLINGERHOUT D, BOGDANOV A JR, MARECOS E, SPEAR M, BREAKEFIELD XO, WEISSLEDER R: Mapping the in vivo distribution of herpes simplex virions. Hum. Gene Ther. (1998) 9(11):1543-1549.
71. SCHELLINGERHOUT D, RAINOV NG, BREAKEFIELD XO, WEISSLEDER R: Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. (2000) 7(19):1648-1655.
72. IKEDA K, ICHIKAWA T, WAKIMOTO H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. (1999) 5(8):881-887. •• Preclinical study applying oncolytic viruses in combination with immunosuppressive chemotherapeutic agents; this study has showed for the first time that host innate immune responses may be detrimental for viral therapy, and presented a therapeutic strategy that strongly increases the efficacy of oncolytic viruses.
73. IKEDA K, WAKIMOTO H, ICHIKAWA T et al.: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. (2000) 74(10):4765-4775.
74. WAKIMOTO H, IKEDA K, ABE T et al.: The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. (2002) 5(3):275-282.
75. KURIYAMA N, KURIYAMA H, JULIN CM, LAMBORN KR, ISRAEL MA: Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model. Cancer Res. (2001) 61(5):1805-1809.
76. MCKEE TD, GRANDI P, MOK W et al.: Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. (2006) 66(5):2509-2513.
77. LOWENSTEIN PR: The case for immunosuppression in clinical gene transfer. Mol. Ther. (2005) 12(2):185-186.
78. FRIEDMAN A, TIAN JP, FULCI G, CHIOCCA EA, WANG J: Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res. (2006) 66(4):2314-2319. • A mathematical model describing the interaction between oncolytic viruses, the host immune system and immunosuppressive drugs; this model has predicted the outcome of preclinical research that has followed.
79. WAKIMOTO H, FULCI G, TYMINSKI E, CHIOCCA EA: Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther. (2004) 11(2):214-223.
80. FULCI G, BREYMANN L, GIANNI D et al.: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. USA (2006) 103(34):12873-12878.
81. LAMFERS ML, FULCI G, GIANNI D et al.: Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol. Ther. (2006) (In Press).
82. DOUGLAS JT, KIM M, SUMEREL LA, CAREY DE, CURIEL DT: Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res. (2001) 61(3):813-817.
83. KASONO K, BLACKWELL JL, DOUGLAS JT et al.: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. (1999) 5(9):2571-2579.
84. ZHOU G, ROIZMAN B: Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells. J. Virol. (2005) 79(9):5272-5277.
85. CHUNG R, SAEKI Y, CHIOCCA EA: B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J. Virol. (1999) 73(9):7556-7564.
86. NAKAMURA H, KASUYA H, MULLEN JT et al.: Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J. Clin. Invest. (2002) 109(7):871-882.
87. KASUYA H, PAWLIK TM, MULLEN JT et al.: Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen. Cancer Res. (2004) 64(7):2561-2567.
88. KAMBARA H, OKANO H, CHIOCCA EA, SAEKI Y: An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res. (2005) 65(7):2832-2839.
89. KANAI R, TOMITA H, SHINODA A et al.: Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence. Gene Ther. (2006) 13(2):106-116.
90. MOHR I, STERNBERG D, WARD S, LEIB D, MULVEY M, GLUZMAN Y: A herpes simplex virus Type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. (2001) 75(11):5189-5196.
91. TODO T, MARTUZA RL, RABKIN SD, JOHNSON PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA (2001) 98(11):6396-6401. • Engineering of a very promising oncolytic virus for brain tumors; although it has not been tested in clinical trials, preclinical research has demonstrated that this virus has significantly increased both safety and replication capacity when used for brain tumors.
92. KO D, HAWKINS L, YU DC: Development of transcriptionally regulated oncolytic adenoviruses. Oncogene (2005) 24(52):7763-7774.
93. BISCHOFF JR, KIRN DH, WILLIAMS A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 274(5286):373-376. •• Describes the first oncolytic virus targeting a specific genetic/molecular feature of cancer cells; even though further research has found that the selectivity of this virus for cancer cells is more complex than what was described here, it has opened a new field of research.
94. FUEYO J, GOMEZ-MANZANO C, ALEMANY R et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 19(1):2-12.
95. GOMEZ-MANZANO C, BALAGUE C, ALEMANY R et al.: A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene (2004) 23(10):1821-1828.
96. FARASSATI F, YANG AD, LEE PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. (2001) 3(8):745-750.
97. SHAH AC, PRICE KH, PARKER JN et al.: Serial passage through human glioma xenografts selects for a deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J. Virol. (2006) 80(15):7308-7315.
98. BOVIATSIS EJ, PARK JS, SENA-ESTEVES M et al.: Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. (1994) 54(22):5745-5751.
99. CHASE M, CHUNG RY, CHIOCCA EA: An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat. Biotechnol. (1998) 16(5):444-448.
100. TYMINSKI E, LEROY S, TERADA K et al.: Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. (2005) 65(15):6850-6857.
101. AGHI M, RABKIN S, MARTUZA RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J. Natl Cancer Inst. (2006) 98(1):38-50.
102. LAMPSON LA: New animal models to probe brain tumor biology, therapy, and immunotherapy: advantages and remaining concerns. J. Neurooncol. (2001) 53(3):275-287. • Comprehensive review on animal models for brain tumor preclinical research; this review clearly shows the difficulty in translating gene therapy preclinical data from the available animal models to humans.
103. BRINSTER RL, CHEN HY, MESSING A, VAN DYKE T, LEVINE AJ, PALMITER RD: Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 37(2):367-379.
104. CORCORAN RB, SCOTT MP: A mouse model for medulloblastoma and basal cell nevus syndrome. J. Neurooncol. (2001) 53(3):307-318.
105. UHRBOM L, HOLLAND EC: Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors. J. Neurooncol. (2001) 53(3):297-305.
106. DING H, GUHA A: Mouse astrocytoma models: embryonic stem cell mediated transgenesis. J. Neurooncol. (2001) 53(3):289-296.
107. EARNEST FT, KELLY PJ, SCHEITHAUER BW et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology (1988) 166(3):823-827.
108. HERHOLZ K, WIENHARD K, HEISS WD: Validity of PET studies in brain tumors. Cerebrovasc. Brain Metab. Rev. (1990) 2(3):240-265.
109. PRICE P: PET as a potential tool for imaging molecular mechanisms of oncology in man. Trends Mol. Med. (2001) 7(10):442-446.
110. JACOBS AH, DITTMAR C, WINKELER A, GARLIP G, HEISS WD: Molecular imaging of gliomas. Mol. Imaging (2002) 1(4):309-335. • Comprehensive review on molecular imaging of gliomas; it clearly shows how gene therapy has impacted the development of this field.
111. CHO JY, XING S, LIU X et al.: Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. (2000) 7(9):740-749.
112. BOLAND A, RICARD M, OPOLON P et al.: Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res. (2000) 60(13):3484-3492.
113. JACOBS A, TJUVAJEV JG, DUBROVIN M et al.: Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. (2001) 61(7):2983-2995.
114. REHEMTULLA A, HALL DE, STEGMAN LD et al.: Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol. Imaging (2002) 1(1):43-55.
115. FLOETH FW, AULICH A, LANGEN KJ, BURGER KJ, BOCK WJ, WEBER F: MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma. Am. J. Neuroradiol. (2001) 22(8):1517-1527.
116. MORANDI E, ZINGARETTI C, CHIOZZOTTO D et al.: A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett. (2006) 231(1):74-86.
117. HUSSAIN SF, YANG D, SUKI D, GRIMM E, HEIMBERGER AB: Innate immune functions of microglia isolated from human glioma patients. J. Transl. Med. (2006) 4:15.
118. CONDEELIS J, POLLARD JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124(2):263-266.